Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target

K. Bodoor, R. Almomani, M. Alqudah, Y. Haddad, W. Samouri

. 2020 ; 21 (5) : 1453-1458. [pub] 20200501

Language English Country Thailand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21012622

OBJECTIVE: HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter - LAT1 as a potential prognosticator and a drug target. METHODS: In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort. RESULTS: Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2- group compared to none in the LAT1-/HER2- group (N=11). CONCLUSION: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.
.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012622
003      
CZ-PrNML
005      
20210507101611.0
007      
ta
008      
210420s2020 th f 000 0|eng||
009      
AR
024    7_
$a 10.31557/APJCP.2020.21.5.1453 $2 doi
035    __
$a (PubMed)32458655
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a th
100    1_
$a Bodoor, Khaldon $u Department of Applied Biology, Jordan University of Science and Technology, Irbid, Jordan
245    10
$a LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target / $c K. Bodoor, R. Almomani, M. Alqudah, Y. Haddad, W. Samouri
520    9_
$a OBJECTIVE: HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter - LAT1 as a potential prognosticator and a drug target. METHODS: In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort. RESULTS: Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2- group compared to none in the LAT1-/HER2- group (N=11). CONCLUSION: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.<br />.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a duktální karcinom prsu $x metabolismus $x patologie $x chirurgie $7 D018270
650    _2
$a lobulární karcinom $x metabolismus $x patologie $x chirurgie $7 D018275
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a přenašeč velkých neutrálních aminokyselin 1 $x metabolismus $7 D027283
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $x metabolismus $x patologie $x chirurgie $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a receptor erbB-2 $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a receptory progesteronu $x metabolismus $7 D011980
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
650    _2
$a triple-negativní karcinom prsu $x metabolismus $x patologie $x chirurgie $7 D064726
655    _2
$a časopisecké články $7 D016428
700    1_
$a Almomani, Rowida $u Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, Jordan
700    1_
$a Alqudah, Mohammad $u Department of Pathology, Jordan University of Science and Technology, Irbid, Jordan
700    1_
$a Haddad, Yazan $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Purkynova, Brno, Czech Republic
700    1_
$a Samouri, Walaa $u Department of Pathology, Jordan University of Science and Technology, Irbid, Jordan
773    0_
$w MED00165404 $t Asian Pacific journal of cancer prevention : APJCP $x 2476-762X $g Roč. 21, č. 5 (2020), s. 1453-1458
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32458655 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101611 $b ABA008
999    __
$a ok $b bmc $g 1650895 $s 1133001
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 5 $d 1453-1458 $e 20200501 $i 2476-762X $m Asian Pacific Journal of Cancer Prevention $n Asian Pac. J. Cancer Prev. $x MED00165404
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options